PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Dawn Svoronos to the company's Board of Directors. Ms. Svoronos most recently served as President of Merck's Europe/Canada region from 2009 to 2011 and as President of Merck inCanada from 2006 to 2009.

"We are thrilled to have Dawn joining our Board of Directors," said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "Dawn brings extensive commercial and leadership experience from her impressive contributions at Merck. Dawn's global commercialization expertise makes her a valuable advisor as we continue expanding access to Translarna worldwide."

Ms. Svoronos has more than 30 years of experience in the pharmaceutical industry, including her tenure as President of Merck & Company's Europe/Canada region. Previously held positions with Merck include President of Merck in Canada, Vice President of Asia Pacific and Vice President of Global Marketing for the Arthritis, Analgesics and Osteoporosis franchise. Ms. Svoronos is currently Chair of the Board of Directors for Theratechnolgies Inc., a specialty pharmaceutical company that trades on the Toronto Stock Exchange. Ms. Svoronos also serves on the board of Medivation Inc., a Nasdaq-listed biopharmaceutical company in San Francisco and is a member of the board of Agnovos Healthcare Company, a privately held organization in New York.

About PTC Therapeutics

PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. Post-transcriptional control processes are the regulatory events that occur in cells during and after a messenger RNA, or mRNA, molecule is copied from DNA through the transcription process. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders and oncology. PTC has discovered all of its compounds currently under development using its proprietary technologies. PTC plans to continue to develop these compounds both on its own and through selective collaboration arrangements with leading pharmaceutical and biotechnology companies. For more information on the company, please visit our website www.ptcbio.com.